Synthetic TLR9 agonists, CpG–ODNs have demonstrated promising direct and immune system-mediated anti-cancer effects against breast cancer in pre-clinical models but they have not been studied in clinical breast cancer trials. This evidence concerns the gene TLR9 and breast carcinoma.